Ascletis Pharma Future Growth

Future criteria checks 0/6

Ascletis Pharma's earnings are forecast to decline at 4.1% per annum while its annual revenue is expected to grow at 117.7% per year. EPS is expected to decline by 3.5% per annum.

Key information

-4.1%

Earnings growth rate

-3.5%

EPS growth rate

Biotechs earnings growth36.2%
Revenue growth rate117.7%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Oct 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:2VJ - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202677-289N/AN/A1
12/31/2025N/A-298N/AN/A1
12/31/2024N/A-281N/AN/A1
6/30/202410-258-299-280N/A
3/31/202433-202-231-212N/A
12/31/202357-145-163-144N/A
9/30/202359-194-169-157N/A
6/30/202362-243-173-171N/A
3/31/202358-279-195-187N/A
12/31/202254-315-217-202N/A
9/30/202266-246-198-182N/A
6/30/202279-176-179-161N/A
3/31/202278-188-167-154N/A
12/31/202177-199-154-147N/A
9/30/202158-234-172-150N/A
6/30/202140-269-190-153N/A
3/31/202137-239-157-119N/A
12/31/202035-209-124-85N/A
9/30/202082-155-86-56N/A
6/30/2020130-100-47-28N/A
3/31/2020152-98-75-51N/A
12/31/2019173-96-103-74N/A
9/30/2019150-92-130-91N/A
6/30/2019127-89-157-107N/A
3/31/2019153-43-146-83N/A
12/31/2018166-7-157-97N/A
9/30/2018154-5-172-134N/A
6/30/2018142-2-188-171N/A
3/31/201891-40N/A-210N/A
12/31/201753-54N/A-198N/A
12/31/201633-27N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2VJ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2VJ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2VJ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2VJ is forecast to have no revenue next year.

High Growth Revenue: 2VJ is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2VJ's Return on Equity is forecast to be high in 3 years time


Discover growth companies